作者
Xiaodie Gao,Zhigang Wang,Lijun Xiong,Fengyao Wu,Xinying Gan,Jinlian Liu,Xiansheng Huang,Juxia Liu,Liling Tang,Yanmei Li,Jinli Huang,Yuping Huang,Wenyang Li,Hongji Zeng,Yunfei Ban,Tingting Chen,Suyuan He,Anni Lin,Fei Han,Xuefeng Guo,Qi Yu,Wei Shu,Bo Zhang,Ruyi Zou,Yong Zhou,Yongfeng Chen,Haibo Tian,Wenjia Wei,Zhen Zhang,Chuandong Wei,Yuhua Wei,Huicong Liu,Yao Hua,Qiang Chen,Zhenyou Zou
摘要
Iron accumulates in the brain with age and catalyzes free radical damage to neurons, thus playing a pathogenic role in Alzheimer's disease (AD). To decrease the incidence of AD, we synthesized the iron-affinitive peptide 5YHEDA to scavenge the excess iron in the senile brain. However, the blood-brain barrier (BBB) blocks the entrance of macromolecules into the brain, thus decreasing the therapeutic effects. To facilitate the entrance of the 5YHEDA peptide, we linked the low-density lipoprotein receptor (LDLR)-binding segment of ApoB-100 to 5YHEDA (named "bs-YHEDA"). The results of intravenous injections of bs-5YHEDA into senescent mice demonstrated that bs-YHEDA entered the brain, increased ferriportin levels, reduced iron and free radical levels, decreased the consequences of neuronal necrosis and ameliorated cognitive disfunction without kidney or liver damage. bs-5YHEDA is a safe iron and free radical remover that potentially alleviates aging and Alzheimer's disease.